Product: BSI CTMS | Industry: Life Science
Starting in late 2019, Occlutech one of the world´s leading suppliers in the area of structural heart disease will be using BSI CTMS for the effective and smooth management of clinical trials.
Occlutech was founded in Germany in 2003, and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for; congenital defects, stroke prevention, and heart failure. The company´s products are sold in over 80 countries globally and the total number of implantations is approaching 80.000, setting the highest standards regarding quality, outcomes and patient safety.
Following an extensive evaluation of a number of CTMS providers, the BSI solution was selected due to a number of factors including usability, functionality and cost effectiveness, and it is anticipated that go-live will take place in less than four months following the first requirements workshop.
“The BSI solution beat the competition thanks to the combination of intuitive usability, its full spectrum of functionality and price.”
Dr. Simon Kordowich
Clinical Project Manager at Occlutech
Flexibility and pricing were important considerations when selecting the winning system, explains Occlutech’s Dr. Simon Kordowich, Clinical Project Manager: “The cloud-based, on-demand offer with very comprehensive CTMS functionality was particularly attractive to us, as it enables us to grow step-by-step. For a monthly per user fee, we receive all the advantages and functions of BSI CTMS from the cloud.”
“Our partnership with BSI will allow us to take our clinical trial management to the next level. We very much look forward to working with them.”
Dr. Luis Martin-Parras
CEO at Occlutech